Last updated on November 2017

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer


Brief description of study

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Detailed Study Description

The purpose of this study is to evaluate the safety and tolerability of INCB039110 in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Clinical Study Identifier: TX15373

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Incyte Corporation

Incyte Corporation
Bethlehem, PA USA
  Connect »